文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒肝肾功能剂量调整

整合临床危险因素与药代动力学参数预测万古霉素肾毒性的新评分模型

Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin-Induced Nephrotoxicity.
PubMed 文献 · Pharmacotherapy · 2026-01-01

本研究基于单中心回顾性队列(2021年4月至2023年3月接受万古霉素治疗的患者),开发并验证了一个整合临床危险因素与药代动力学参数的评分模型,用于预测万古霉素诱导的肾毒性。该模型包含稳态AUC(0-8分)、联用他唑巴坦/哌拉西林(2分)、使用袢利尿剂(1分)和慢性肝病(2分),在推导队列和验证队列中ROC AUC分别为0.79和0.84,且NRI和IDI均显著优于传统AUC模型(p<0.001)。

要点

  • 新评分模型包含稳态AUC、联用他唑巴坦/哌拉西林、袢利尿剂和慢性肝病四个预测因子。
  • 模型预测性能良好,推导队列ROC AUC为0.79,验证队列为0.84。
  • 模型在NRI和IDI上均显著优于传统AUC模型(p<0.001)。

核心结论

  • 整合临床危险因素与药代动力学参数的评分模型可能改善万古霉素诱导肾毒性的风险分层,并促进个体化给药策略。

研究设计与样本

  • 单中心回顾性队列研究,纳入2021年4月至2023年3月接受万古霉素治疗的患者,采用多变量logistic回归识别独立危险因素并构建评分模型。

主要发现

  • 评分模型由稳态AUC(0-8分)、联用他唑巴坦/哌拉西林(2分)、使用袢利尿剂(1分)和慢性肝病(2分)组成。
  • 推导队列ROC AUC为0.79(95%CI: 0.71-0.87),验证队列为0.84(95%CI: 0.72-0.96)。
  • NRI在推导队列为0.78(95%CI: 0.47-1.08),验证队列为1.23(95%CI: 0.79-1.67)。
  • IDI在推导队列为0.07(95%CI: 0.04-0.11),验证队列为0.27(95%CI: 0.15-0.39),p<0.001。

临床怎么用

  • 临床可利用该评分模型对接受万古霉素治疗的患者进行肾毒性风险分层,辅助个体化给药决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vancomycin (VCM), a first-line treatment option for infections caused by methicillin-resistant Staphylococcus aureus, has been reported to cause nephrotoxicity even within therapeutic concentration ranges. Traditional therapeutic drug monitoring strategies rely primarily on the area under the concentration-time curve (AUC), without adequately accounting for multiple clinical risk factors associated with nephrotoxicity. OBJECTIVE: The present study aimed to develop a novel scoring model that integrates clinical risk factors and pharmacokinetic parameters to predict VCM-induced nephrotoxicity and validate its predictive performance. METHODS: We conducted a single-center retrospective cohort study on patients who received VCM therapy between April 2021 and March 2023. A multivariable logistic regression analysis was performed to identify independent risk factors for VCM-induced nephrotoxicity, and regression coefficients were used to construct the scoring model. The predictive performance of the proposed model was compared with a conventional AUC-based model using the area under the receiver operating characteristic curve (ROC AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). RESULTS: The scoring model consisted of the following components: the steady-state area under the concentration-time curve (0-8 points), the concomitant use of tazobactam/piperacillin (2 points), the use of loop diuretics (1 point), and the presence of chronic liver disease (2 points). The proposed model demonstrated high predictive performance, with ROC AUC values of 0.79 (95% confidence interval [CI]: 0.71-0.87) in the derivation cohort and 0.84 (95% CI: 0.72-0.96) in the validation cohort. Furthermore, the proposed model showed significantly better performance than the conventional model in terms of NRI (derivation cohort: 0.78, 95% CI: 0.47-1.08; validation cohort: 1.23, 95% CI: 0.79-1.67) and IDI (derivation cohort: 0.07, 95% CI: 0.04-0.11; validation cohort: 0.27, 95% CI: 0.15-0.39) (p < 0.001). CONCLUSION: The scoring model developed in the present study may enhance risk stratification for VCM-induced nephrotoxicity and contribute to advances in individualized dosing strategies in clinical practice.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Matsuki Y, Sako KI, Kozima Y, et al. Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin-Induced Nephrotoxicity. Pharmacotherapy. 2026. PMID: 41605883. doi:10.1002/phar.70111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。